Two Sigma Advisers LP lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 38.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 455,020 shares of the biopharmaceutical company’s stock after selling 281,100 shares during the quarter. Two Sigma Advisers LP owned approximately 0.31% of Halozyme Therapeutics worth $6,657,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Bank of Montreal Can increased its position in shares of Halozyme Therapeutics by 80.4% in the 4th quarter. Bank of Montreal Can now owns 2,011 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 896 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $123,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Halozyme Therapeutics by 33.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,791 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 2,430 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of Halozyme Therapeutics during the 4th quarter valued at about $157,000. Finally, Verition Fund Management LLC bought a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $182,000. Institutional investors own 83.23% of the company’s stock.
Shares of NASDAQ:HALO traded down $0.39 during trading on Friday, reaching $15.97. The company had a trading volume of 1,062,740 shares, compared to its average volume of 816,237. The firm has a market cap of $2.32 billion, a P/E ratio of -28.52 and a beta of 1.85. Halozyme Therapeutics, Inc. has a twelve month low of $13.24 and a twelve month high of $20.54. The company has a current ratio of 2.86, a quick ratio of 2.71 and a debt-to-equity ratio of 0.14.
A number of equities research analysts recently weighed in on HALO shares. Zacks Investment Research raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $17.00 price objective for the company in a research report on Tuesday, January 8th. BidaskClub raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 15th. Cantor Fitzgerald reissued a “buy” rating and set a $24.00 target price on shares of Halozyme Therapeutics in a research note on Monday, February 4th. JMP Securities reissued a “buy” rating and set a $21.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday, February 27th. Finally, ValuEngine lowered shares of Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.17.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/21/two-sigma-advisers-lp-reduces-holdings-in-halozyme-therapeutics-inc-halo.html.
Halozyme Therapeutics Company Profile
There is no company description available for Halozyme Therapeutics Inc
Featured Article: Why is the conference call important?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.